- IPO AveXis (NASDAQ:AVXS) is faring a bit better than fellow IPO Proteostasis Therapeutics (NASDAQ:PTI) although down 13% from its $20 offer price on light turnover of 760K shares.
- AveXis priced its debut at the midpoint of its proposed range of $19 - 21 so, all things considered, not too bad for a bad day for an IPO. Proteostasis is changing hands at more than 52% below its original midpoint of $12 - 14.
- Previously: AveXis on deck for IPO (Feb. 8)